HaploX Biotechnology

What HaploX Biotechnology does

HaploX Biotechnology is a Shenzhen-based precision oncology company founded in 2014 that provides clinical genetic testing, liquid biopsy, and multi-omics services to biopharmaceutical companies, hospitals, clinicians, and cancer patients. The company operates a comprehensive genetic testing platform spanning pan-solid tumor profiling, minimal residual disease (MRD) detection, hereditary cancer screening, and full-cycle cancer management, and supports international customers through its Hong Kong Science Park laboratory serving Europe, the Americas, and Asia-Pacific.

At the core of HaploX's technology is the LIUDUS® molecular diagnostics platform, which integrates patented software, machine learning models, and proprietary data libraries throughout the NGS workflow to enable ultra-sensitive variant detection, including a 0.005% minimum detection limit at 100,000X sequencing depth for MRD applications. The company holds 86 patents and 95+ software copyrights supporting a suite of products including the HapOnco® clinical panels (WESPlus, StarPanel, CorePanel, BasicPanel, mClear, mClean, PARPrion, Hereditary), the GeneBrain™ bioinformatics analysis and interpretation platform, the HapLab® LIMS, and the HapYun® cloud platform. Founder and CTO Dr. Chen Shifu developed Fastp, an open-source bioinformatics tool cited over 20,000 times and used by institutions including Harvard, NCI, and MIT.

HaploX generates revenue across four streams: clinical genetic testing services for cancer patients, biopharma R&D services (central laboratory, patient recruitment, companion diagnostics) for over 700 pharma and biotech clients, CE-IVD marked reagent kit sales, and research-grade multi-omics services spanning DNA/RNA sequencing, single-cell, proteomics, and metabolomics. Distribution is anchored by an in-house sales force of over 300 professionals across more than 20 Chinese provinces and 500+ Tertiary A hospitals, with international reach via the Hong Kong lab (CAP-accredited 2026) and EU CE-IVDR certified products. The company maintains CAP, CLIA, EMQN, ISO 13485, and CE-IVDR certifications and has achieved perfect scores in more than 400 proficiency tests.

Name

HaploX Biotechnology

Legal name

HaploX GeneTech (Hong Kong) Limited

Website

https://haplox.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

501–1,000 employees

Short description

HaploX Biotechnology is a Shenzhen-based precision oncology company providing clinical genetic testing, liquid biopsy, and multi-omics services to biopharma firms, hospitals, and clinicians across China, Europe, the Americas, and Asia-Pacific.

Ownership category

akta.pro rank

Product category

Precision Oncology Genetic Testing

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industries

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)

Keywords

• Genetic sequencing services
• Liquid biopsy diagnostics
• Multi-omics research
• Companion diagnostics
• Precision oncology testing

Headquarters

HQ city

Shenzhen

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Clinical Genetic Testing Services: HaploX provides clinical genetic testing to solid tumor patients and healthcare providers, covering the full cancer management cycle from early screening through treatment guidance and MRD monitoring. Testing reports are delivered within 7-10 days. Revenue is generated per test, likely on a per-sample basis.
2. Biopharma Research Services: HaploX provides R&D genetic testing services to over 700 biopharmaceutical companies and research institutes, including central laboratory services, patient recruitment, exploratory research, and companion diagnostics. Revenue is generated through project-based service contracts with pharma clients.
3. IVD Product Sales: HaploX sells CE-IVD marked reagent kits including nucleic acid extraction kits (HapEnrich®), tumor NGS assay kits (HapOnco® CorePanel, StarPanel, WESPlus, mClean, PARPrion), and GeneBrain™ bioinformatics system. These are sold as 24-test kits or other packing specifications.
4. Multi-Omics Tech Services: Research services spanning DNA sequencing, RNA sequencing, single-cell sequencing, metabolomics, and proteomics offered to academic and pharma research clients. Revenue generated through project-based service contracts with defined deliverables.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

HaploX Biotechnology is a precision oncology company providing clinical-grade genetic testing for solid tumors (HapOnco® product line including WESPlus, StarPanel, CorePanel, MRD detection, and hereditary cancer panels), multi-omics research services spanning DNA/RNA sequencing, single-cell, proteomics and metabolomics, and biopharma services including central laboratory, patient recruitment, exploratory research, and companion diagnostics co-development. The company manufactures and sells CE-IVD marked NGS reagent kits and the GeneBrain™ bioinformatics system, all powered by its proprietary LIUDUS® molecular diagnostics platform. Services are delivered to biopharmaceutical companies, hospitals, and academic research institutions across China and internationally via its Hong Kong International Center.

Product overview

HaploX Biotechnology is a precision oncology company offering a comprehensive portfolio of genetic testing solutions organized into three main service categories: Clinical Products (clinical-grade genetic testing for solid tumors including pan-cancer WES and panel testing, MRD detection, and hereditary cancer screening under the HapOnco® brand), Multi-Omics Tech Services (research-grade sequencing services covering DNA/RNA sequencing, proteomics, and metabolomics), and Biopharma Services (central laboratory, patient recruitment, exploratory research, and companion diagnostics). The company operates its proprietary LIUDUS® molecular diagnostics platform and Laboratory Testing Platform, and offers CE-IVD marked reagent kits and the GeneBrain™ bioinformatics system. Services are supported by the HapLab® laboratory information management system and HapYun® cloud platform for digital, automated operations.

Differentiator

Problem solved

Functional benefit

Brands

• HapOnco: Comprehensive cancer genetic testing product line including WESPlus, StarPanel, PARPrion, CorePanel, BasicPanel, mClear, mClean, and Hereditary Cancer testing products
• HapEnrich
• LIUDUS
• GeneBrain
• VarSingal
• Fastp

Products and services

• HapOnco® WESPlus High-throughput whole exome sequencing (WES) clinical genetic testing product for solid tumor patients providing comprehensive tumor genome assessment, big data analysis, and professional medical interpretation for precise clinical diagnosis and treatment guidance. Includes targeted therapy, immunotherapy, endocrine therapy, hereditary tumors, and viral infections coverage.
• HapOnco® Star (StarPanel) Clinical 1326-gene testing panel for solid tumors detecting important gene variations related to targeted therapy, immunotherapy, chemotherapy, endocrine therapy, hereditary tumors, and virus typing (HBV, HPV, EBV). Supports 20,000X ctDNA ultra-high-depth sequencing detecting mutations as low as 0.3%.
• HapOnco® PARPrion HRD (Homologous Recombination Deficiency) gene testing product for guiding PARP inhibitor treatment. Analyzes BRCA1/2, LOH, TAI, and LST to comprehensively assess HRD status.
• HapOnco® mClear Personalized MRD testing for solid tumors using tumor-informed analysis. Based on WESPlus results, creates patient-specific gene panels with up to 40 mutation sites as molecular tags, achieving 100,000X ultra-high sequencing depth with 0.005% minimum detection limit.
• HapOnco® mClean Fixed MRD testing series designed for lung cancer, digestive tract cancer, and hepatobiliary/pancreatic cancer patients. Uses LIUDUS® molecular diagnostic technology platform and core bioinformatics technology for accurate monitoring of ultra-low-frequency molecular residuals.
• HapOnco® CorePanel Clinical 136-gene testing panel covering genes related to lung cancer, gastrointestinal tumors, hepatopancreatobiliary tumors, breast cancer, gynecological tumors, urinary system tumors, and central nervous system tumors. Evaluates targeted therapy, immunotherapy, chemotherapy, and heredity.
• HapOnco® BasicPanel Focused gene panels including HapOnco® Lung Cancer BasicPanel (11 genes including 8 NCCN-recommended targetable driver genes) and HapOnco® Colorectal Cancer BasicPanel (23 genes with 7 fusion variants and 25 SNP loci for chemotherapy responses).
• HapOnco® Hereditary Cancer Hereditary cancer gene testing product detecting genes related to tumor heritability for clinical diagnosis and treatment plan development. Includes specific panels for breast/gynecological cancer and colorectal cancer.
• IVD Products (NGS Assay Kits) CE-IVD marked NGS solutions portfolio including HapOnco® CorePanel Genomic Profiling Kit (tissue and liquid), StarPanel Genomic Profiling Kit (tissue and liquid), WESPlus Whole Exome Sequencing Kit, mClean MRD Detection Kits (Lung Cancer, Digestive Cancers), PARPrion HRD Score Detection Kit, and HapEnrich® Nucleic Acid Extraction Kits. Packing specifications: 24 tests/kit for assay kits, 48/96 tests/box for extraction kits.
• GeneBrain™ Cancer Genomics Insight System Tumor NGS intelligent analysis and interpretation platform integrating data demultiplexing, data analysis, report interpretation, sample management, data management, and knowledge base management. Enables intelligent and automated processing from raw sequencing data to final reports, combining high-performance computing and storage capabilities.
• Multi-Omics Tech Services Comprehensive research services integrating high-throughput sequencing, long-read sequencing, and mass spectrometry technologies. Covers genomics (WGS, WES, Plant/Animal resequencing), transcriptomics (mRNA, Whole Transcriptome, lncRNA, circRNA, miRNA), proteomics (Astral-DIA, Astral-InDepth Blood), and metabolomics (Untargeted, Hydrophilic, Plus, Targeted).
• Biopharma Services Comprehensive services from genotypic screening to clinical and genomic data analysis including genetic screening for patient enrollment, biomarker discovery, companion diagnostic co-development, research cooperation, and marketing collaboration. Served over 700 biopharmaceutical companies.
• LIUDUS® Platform Proprietary molecular diagnostics platform (Low-input, Ultra-deep, Ultra-sensitive) forming the cornerstone of liquid biopsy capabilities. Integrated into efficient, digital NGS full-process analysis solution, seamlessly configured within HaploX's HapLab® LIMS and HapYun® cloud platform. Enables ultra-sensitive variant detection with 0.005% limit for MRD at 100,000X ultra-high-depth sequencing.

Quantifiable outcome

• MRD detection sensitivity of 0.005% with 100,000X ultra-high-depth sequencing
• +5 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Partnerships

Three partnerships are on record, tiered minor and core.

• European Society of Human Genetics (ESHG)minorOthers · 13 June 2026HaploX participated as an exhibitor at the 59th ESHG 2026 summit in Gothenburg, Sweden (June 13-16, 2026), which gathered approximately 7,000 genetic specialists from more than 90 nations. HaploX showcased its proprietary core technologies and full product portfolio, including precision medicine portfolio, multi-omics capabilities, CE-IVD solutions, and global collaboration strategy.
• 10x GenomicscoreTechnology or Integration · 6 May 2026HaploX partnered with 10x Genomics to launch next-generation high-throughput spatial transcriptomics services powered by the 10x Genomics Atera platform globally in Q3 2026. The Atera platform unifies whole-transcriptome coverage, single-cell-equivalent sensitivity, and high-throughput scalability. HaploX will provide standardized, one-stop spatial multi-omics research services covering sample preparation, experimental processing, high-throughput data analysis, professional interpretation, and interactive reporting.
• HaploX Partner Network (General)coreChannel Partner/ Reseller/ DistributorHaploX operates a channel partner network for IVD product distribution and service delivery. The company extends partnership opportunities globally for IVD distributors and service partners. A dedicated 'Become a Partner' program exists to explore IVD products distribution and multi-omics service partnerships internationally.

Scale indicators15 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat6 records

Key highlights7 records

Customer concentration

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HaploX Biotechnology